4-Fluoro-N-methyl-N-[1-[4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl]-4-piperidinyl]-2-(trifluoromethyl)benzamide LY 2940680

Name	LY2940680
Synonyms	LY2940680 Taladegib Taladegib (LY2940680) LY2940680 (Taladegib) Taladegib hydrochloride 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluo 4-Fluoro-N-methyl-N-[1-[4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl]-4-piperidinyl]-2-(trifluoromethyl)benzamide 4-Fluoro-N-methyl-N-[1-[4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl]-4-piperidinyl]-2-(trifluoromethyl)benzamide LY 2940680
CAS	1258861-20-9

Molecular Formula	C26H24F4N6O
Molar Mass	512.5
Density	1.39
Boling Point	703.5±60.0 °C(Predicted)
Solubility	DMSO 0.66 mg/mL (1.28 mM); Water <1 mg/mL (<1 mM); Ethanol 2 mg/mL (3.9 mM)
pKa	7.94±0.30(Predicted)
Storage Condition	-20℃
MDL	MFCD21609264
In vitro study	LY2940680 inhibits cancer growth in cell lines containing a mutation in the gene encoding Smoothened that researchers had previously observed in patient with cancer who developed resistance to vismodegib.
In vivo study	LY2940680 has excellent pharmacokinetic properties in rodent and non-rodent species. LY2940680 administrated orally treats Ptch+/- p53-/- transgenic mice which spontaneously develop medulloblastoma, produces remarkable efficacy and significantly improves their survival. LY2940680 reveals rapid kinetics of anti-tumor activity through magnetic resonance imaging of these mice, and LY2940680 induces Caspase-3 activity and reduces proliferation by immunohistochemistry analysis of medulloblastoma tumors. LY2940680 inhibits Hh regulated gene expression in the subcutaneous xenograft tumor stroma and produces significant anti-tumor activity.

LY2940680 binds to Smoothened(Smo) receptor and effectively inhibits Hedgehog(Hh) signaling pathway. Phase 1/2.

Last Update：2022-10-16 17:41:23

biological activity	Taladegib (LY2940680) binds to Smoothened(Smo) receptor to effectively inhibit Hedgehog(Hh) signaling pathway. Phase 1/2. Taladegib (LY2940680) binds to Smoothened(Smo) receptor to effectively inhibit Hedgehog(Hh) signaling pathway. Phase 1/2.
in vitro study	LY2940680 inhibits cancer growth in cell lines containing a mutation in the gene encoding Smoothened that researchers had previously observed in patient with cancer who developed resistance to vismodegib.
in vivo study	LY2940680 has excellent pharmacokinetic properties in rodent and non-rodent species. LY2940680 administrated orally treat Ptch /- p53-/- transgenic mice which spontaneously develop medulloblastoma, produces remarkable efficacy and significantly improves their survival. LY2940680 reveals rapid kinetics of anti-tumor activity through magnetic resonance imaging of these mice, and LY2940680 induces Caspase-3 activity and reduces proliferation by immunohistochemistry analysis of medulloblastoma tumors. LY2940680 inhibits Hh regulated gene expression in the subcutaneous xenograft tumor stroma and produces significant anti-tumor activity.
target	TargetValue Smoothened
Target	Value

Last Update：2024-04-09 19:05:03

Product Name: LY2940680 Visit Supplier Webpage Request for quotation
CAS: 1258861-20-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

Product Name: LY2940680 Visit Supplier Webpage Request for quotation
CAS: 1258861-20-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

View History

4-Fluoro-N-methyl-N-[1-[4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl]-4-piperidinyl]-2-(trifluoromethyl)benzamide LY 2940680 Request for Quotation